Allogeneic haematopoietic stem cell transplantation with reduced intensity conditioning regimens ("minitransplants")

Swiss Medical Weekly

Volumn 131, Issue 5-6, 2001, Pages 59-64

  Schanz, U ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; IDARUBICIN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ALLOGRAFT; BONE MARROW TOXICITY; CANCER; CANCER SURVIVAL; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; POSTOPERATIVE COMPLICATION; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0035100110     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem cell transplantation
2. Bone-marrow transplantation (first of two parts)
3. Bone-marrow transplantation (second of two parts)
4. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
5. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
6. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines
7. Treatment of murine leukemia with X-rays and homologous bone marrow
8. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
9. T-cell depletion of HLA-identical transplants in leukemia
10. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
11. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
12. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
13. Stable mixed hematopoietic chimerism in DLA-identical litter-mare dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
14. Mini-allografts: Ongoing trials in humans
15. Mixed chimerism: Preclinical studies and clinical applications
16. Hematopoietic stem cell transplants (HSCT) from HLA-mismatched unrelated donors after minimal conditioning
17. Higher rate of graft failure after dose reduced conditioning and stem cell transplantation from unrelated than from related donors
18. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
19. Effect of mixed chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia
20. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and Non-Hodgkin's lymphoma
21. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment of lymphoid malignancies
22. Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: Harnessing graft-versus-leukaemia without myeloablative therapy
23. Low intensity regimens with allogeneic haematopoietic stem cell transplantation as treatment of hematologic neoplasia
24. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
25. Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: "miniallografts" are no small matter